Logo image of CLNN

CLENE INC (CLNN) Stock Fundamental Analysis

NASDAQ:CLNN - Nasdaq - US1856342019 - Common Stock - Currency: USD

2.6  -0.12 (-4.41%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CLNN. CLNN was compared to 562 industry peers in the Biotechnology industry. CLNN has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CLNN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLNN has reported negative net income.
CLNN had a negative operating cash flow in the past year.
In the past 5 years CLNN always reported negative net income.
In the past 5 years CLNN always reported negative operating cash flow.
CLNN Yearly Net Income VS EBIT VS OCF VS FCFCLNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

CLNN has a Return On Assets of -144.13%. This is amonst the worse of the industry: CLNN underperforms 83.99% of its industry peers.
Industry RankSector Rank
ROA -144.13%
ROE N/A
ROIC N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLNN Yearly ROA, ROE, ROICCLNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K

1.3 Margins

The Gross Margin of CLNN (79.53%) is better than 84.70% of its industry peers.
CLNN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CLNN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
CLNN Yearly Profit, Operating, Gross MarginsCLNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

CLNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLNN has been increased compared to 1 year ago.
The number of shares outstanding for CLNN has been increased compared to 5 years ago.
CLNN has a worse debt/assets ratio than last year.
CLNN Yearly Shares OutstandingCLNN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLNN Yearly Total Debt VS Total AssetsCLNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CLNN has an Altman-Z score of -17.77. This is a bad value and indicates that CLNN is not financially healthy and even has some risk of bankruptcy.
CLNN has a Altman-Z score of -17.77. This is amonst the worse of the industry: CLNN underperforms 84.52% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.77
ROIC/WACCN/A
WACC11.98%
CLNN Yearly LT Debt VS Equity VS FCFCLNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.57 indicates that CLNN should not have too much problems paying its short term obligations.
CLNN has a worse Current ratio (1.57) than 80.78% of its industry peers.
CLNN has a Quick Ratio of 1.56. This is a normal value and indicates that CLNN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.56, CLNN is not doing good in the industry: 80.07% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.56
CLNN Yearly Current Assets VS Current LiabilitesCLNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.88% over the past year.
Looking at the last year, CLNN shows a very negative growth in Revenue. The Revenue has decreased by -48.18% in the last year.
CLNN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -21.98% yearly.
EPS 1Y (TTM)42.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
Revenue 1Y (TTM)-48.18%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-46.47%

3.2 Future

CLNN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.67% yearly.
The Revenue is expected to grow by 319.10% on average over the next years. This is a very strong growth
EPS Next Y43.08%
EPS Next 2Y26.74%
EPS Next 3Y31.55%
EPS Next 5Y28.67%
Revenue Next Year-32.04%
Revenue Next 2Y246.56%
Revenue Next 3Y544.03%
Revenue Next 5Y319.1%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLNN Yearly Revenue VS EstimatesCLNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CLNN Yearly EPS VS EstimatesCLNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLNN. In the last year negative earnings were reported.
Also next year CLNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLNN Price Earnings VS Forward Price EarningsCLNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLNN Per share dataCLNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4 -5

4.3 Compensation for Growth

CLNN's earnings are expected to grow with 31.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.74%
EPS Next 3Y31.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLENE INC

NASDAQ:CLNN (5/13/2025, 11:13:48 AM)

2.6

-0.12 (-4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24 2025-03-24/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners13.69%
Inst Owner Change-2.33%
Ins Owners25.17%
Ins Owner Change0%
Market Cap23.14M
Analysts81.54
Price Target43.86 (1586.92%)
Short Float %2.84%
Short Ratio2.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.14%
Min EPS beat(2)-91.95%
Max EPS beat(2)9.66%
EPS beat(4)2
Avg EPS beat(4)-15.58%
Min EPS beat(4)-91.95%
Max EPS beat(4)30.25%
EPS beat(8)4
Avg EPS beat(8)-12.26%
EPS beat(12)7
Avg EPS beat(12)6.35%
EPS beat(16)9
Avg EPS beat(16)-4.27%
Revenue beat(2)0
Avg Revenue beat(2)-18.3%
Min Revenue beat(2)-31.37%
Max Revenue beat(2)-5.23%
Revenue beat(4)0
Avg Revenue beat(4)-22.3%
Min Revenue beat(4)-41.81%
Max Revenue beat(4)-5.23%
Revenue beat(8)2
Avg Revenue beat(8)1.38%
Revenue beat(12)4
Avg Revenue beat(12)8.5%
Revenue beat(16)8
Avg Revenue beat(16)39.54%
PT rev (1m)-4.8%
PT rev (3m)-14.34%
EPS NQ rev (1m)-3.26%
EPS NQ rev (3m)-16.8%
EPS NY rev (1m)3.07%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-14.88%
Revenue NQ rev (3m)-43.25%
Revenue NY rev (1m)-17.58%
Revenue NY rev (3m)-12.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 67.66
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.94
EYN/A
EPS(NY)-3.38
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0.04
BVpS-1
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -144.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.53%
FCFM N/A
ROA(3y)-101.99%
ROA(5y)-69.93%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.02%
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.91%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.56
Altman-Z -17.77
F-Score2
WACC11.98%
ROIC/WACCN/A
Cap/Depr(3y)176.04%
Cap/Depr(5y)141.46%
Cap/Sales(3y)385.66%
Cap/Sales(5y)305.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-55%
EPS Next Y43.08%
EPS Next 2Y26.74%
EPS Next 3Y31.55%
EPS Next 5Y28.67%
Revenue 1Y (TTM)-48.18%
Revenue growth 3Y-21.98%
Revenue growth 5YN/A
Sales Q2Q%-46.47%
Revenue Next Year-32.04%
Revenue Next 2Y246.56%
Revenue Next 3Y544.03%
Revenue Next 5Y319.1%
EBIT growth 1Y18.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29%
EBIT Next 3Y31.93%
EBIT Next 5Y64.33%
FCF growth 1Y30.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.32%
OCF growth 3YN/A
OCF growth 5YN/A